INDIVIOR MAKES STATEMENT ON COURT DECISION

RNS Number : 9478H

Indivior PLC

20 November 2018

 

INDIVIOR MAKES STATEMENT ON COURT DECISION

"Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy's Laboratories ("DRL"). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio.

The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed."

 

END

 

 

MSCLLFFELELIFIT